A Male Birth Control Gel Is Getting Closer to Reality
(Bloomberg) -- U.S. government scientists will test an experimental birth control method for men, which would be a major advance in contraception and bring more equality to a family planning burden borne largely by women.
The study is being conducted by the National Institutes of Health and will involve 420 couples. The experimental treatment is a gel, applied to the back and shoulders, that combines two types of hormones to halt the production of sperm while maintaining the energy and libido benefits of testosterone.
“This gel would be the first user-controlled method of contraception for men since the introduction of the condom,” said Diana Blithe, chief of the contraceptive development program at the National Institute of Child Health and Human Development. “We hope it will be an acceptable form of contraception that couples will want to use.”
The gel is a mix of progestin and testosterone, and researchers will examine how successful the gel is at preventing pregnancies. People who rely on condoms have a 12 percent to 13 percent failure rate, while relying on hormone-based birth control pills fails about 7 percent of the time.
“There are some men who may like to control their own fertility, who may or may not be in a monogamous relationship,” said Blithe, who is an investigator for the trial, in a telephone interview. “This would be an option for them.”
A New Method?
Millions of women around the world use birth control, which has been around for decades as a reliable, relatively convenient form of contraception. While many women would likely want to maintain control over the contraceptive method used in a sexual encounter, some either can't take the pill or prefer not to.
Blithe said that the limited options for men led several couples to reach out in advance of the study asking to participate. Earlier research in men alone shows that the approach reduces sperm production and that it rebounds after the gel is stopped, without causing serious side effects.
The NIH researchers crafted the gel with the Population Council, a nonprofit group that works on reproductive health issues. The Council helped develop RU486, or mifepristone, a pill that can be used to end an early pregnancy. Blithe said that if the gel for men is successful, a commercial partner would be found to help sell it.
Testosterone Levels
The drug is formulated as a gel since testosterone is cleared too quickly from the body when it's taken as a pill. The progestin in the gel, called Nestorone, blocks the natural production of testosterone in the testes, where sperm is made. The testosterone replaces the hormone in the blood.
“You are cutting it off at the source, but replacing it everywhere else at a levels that keeps everything else functioning normally,” Blithe said, pointing out that testosterone levels in the testes are 50 times higher than the amount normally found in the blood.
The researchers will track men for four to 12 weeks to ensure their sperm production has fallen significantly enough to prevent conception, with women using an alternative form of birth control just in case. After that, couples will rely on the gel alone. If the results are positive, another larger trial will be needed before the product could get approval.
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net
To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy Annett
©2018 Bloomberg L.P.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.